Erythema Toxicum Neonatorum: Benign Newborn Rash

Overview of Erythema Toxicum Neonatorum

Erythema toxicum neonatorum (ETN) is one of the most common benign skin conditions in newborn infants, occurring in 24-72% of full-term infants and 5-15% of preterm infants. The condition presents with an evanescent rash consisting of erythematous macules, papules, or small pustules that wax and wane without leaving permanent marks. ETN typically appears during the first 24-48 hours of life but may develop up to 2 weeks of age. Despite the somewhat alarming appearance and the word "toxicum" suggesting toxicity, ETN is completely benign, self-limited, and requires no treatment beyond reassurance. Understanding the benign nature of this common condition helps healthcare providers and parents avoid unnecessary concern and inappropriate interventions.

Epidemiology and Etiology

Erythema toxicum neonatorum is extraordinarily common, affecting more than 50% of healthy full-term infants. The incidence is lower in preterm infants, with rates decreasing as gestational age decreases. The exact cause of ETN remains somewhat unclear. The condition is not related to infection, maternal toxemia (despite its name), heat, sebum, or any other toxic agent. Histologic examination reveals eosinophilic infiltration, suggesting possible reaction to normal skin flora or a developmentally-determined response of neonatal skin. Some researchers hypothesize that ETN represents a self-limited response to colonization with normal flora or possibly to the irritant effects of amniotic fluid residue on the skin. The condition is not contagious and does not require isolation or special infection control measures.

Clinical Presentation

Erythema toxicum typically presents as clustered erythematous macules, papules, or small pustules scattered over the face, trunk, and extremities. A characteristic feature is the evanescent nature of the lesions, meaning they rapidly appear and disappear. Individual lesions may persist for hours to days, but new lesions develop in different locations, creating the appearance of a changing rash. The lesions are typically 1-3 millimeters in size. Pustules when present contain clear fluid and PMN predominance on Gram stain, not organisms (sterile pustules). The central area of papules may demonstrate a yellowish color due to the presence of eosinophils. Systemic symptoms are absent; infants appear entirely well with no fever or other constitutional symptoms. The rash does not blanch completely with pressure.

Distinguishing Features and Diagnosis

Diagnosis is primarily clinical based on characteristic appearance and timing. The combination of evanescent papulopustular lesions in a newborn appearing in the first days of life is typically diagnostic. Smearing of pustule contents reveals predominantly eosinophils on Gram stain, which is helpful when diagnosis is questioned. Biopsy shows dermal eosinophilic infiltrate, confirming the diagnosis when histology is obtained. However, biopsy is not indicated for typical presentations. The key distinguishing features that help exclude infection include the lack of systemic symptoms, the sterile nature of pustules, the evanescent course, and the excellent health of the affected infant.

Differential Diagnosis

While ETN is readily recognized, providers should maintain a differential diagnosis for pustular eruptions in newborns. Neonatal herpes simplex virus presents with vesicles (not pustules), systemic symptoms, and requires urgent evaluation and treatment. Congenital varicella presents with characteristic vesicular lesions and systemic illness. Congenital syphilis presents with specific patterns and systemic findings. Incontinentia pigmenti presents with linear vesicles on the extremities in specific patterns. Bullous impetigo presents with larger bullae and may indicate infection. Neonatal pustulosis related to maternal infection requires investigation. The evanescent, benign course of true ETN, combined with excellent infant health and characteristic appearance, typically allows confident diagnosis clinically.

Management and Natural Course

Erythema toxicum requires no treatment. The condition is self-limited and resolves spontaneously, typically within 5-7 days, though individual lesions may persist longer. No topical treatments, oral medications, or other interventions are indicated. Parents should be reassured that the condition is completely benign and will resolve without any intervention or sequelae. The rash does not scar or leave any permanent marks. No isolation from other infants is necessary, as the condition is not contagious. Regular infant care including bathing and diaper changes can continue without modification.

Parental Education

Clear explanation to parents is essential, as the appearance of the rash can be concerning. Parents should be informed that ETN is extraordinarily common in healthy newborns, completely benign, and will resolve without treatment within a few days to a week. The changing nature of the rash should be explained, so parents understand that new lesions appearing as others fade is expected and not concerning. Emphasizing that their infant is healthy and well helps alleviate anxiety. No follow-up appointments or specialist consultations are necessary for uncomplicated ETN.

Frequently Asked Questions

Is this a serious infection? No. Despite the word "toxicum," this is not a toxic condition and is not caused by infection. It is completely benign.

Will it spread to other infants? No. Erythema toxicum is not contagious. It does not spread to other babies or caregivers.

Why does the rash keep changing? ETN is characterized by lesions that appear and disappear (evanescent). This changing appearance is normal and expected.

Will this leave scars? No. ETN resolves without scarring or any permanent skin changes.

How long until it's gone? Most cases resolve within 5-7 days, though some individual lesions may persist up to 14 days.

References